RNA-based gene therapy to silence harmful DUX4 in FSHD
CRISPR-Cas13 gene therapy and RNA editing for Facioscapulohumeral muscular dystrophy (FSHD)
Researchers are developing RNA-only gene therapies that cut DUX4 messages to protect muscles in people with FSHD.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst Nationwide Children's Hosp NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project ID | NIH-11139605 on NIH RePORTER |
What this research studies
This project aims to stop the toxic DUX4 protein that causes muscle damage in FSHD by using CRISPR-Cas13 and other RNA-editing tools that cut RNA, not DNA. The team packages these RNA-targeting systems into AAV vectors and tests them in animal models that mimic human FSHD to see if muscle DUX4 levels fall and muscle health improves. Because the methods edit RNA rather than DNA, they avoid permanent genome changes, which may lower some safety concerns compared with DNA-cutting approaches. These RNA-editing tools are very new and this work represents the first in vivo gene-therapy-style tests for FSHD, so results will guide whether future human trials are possible.
Who could benefit from this research
Good fit: People with genetically confirmed FSHD (DUX4-linked, 4q35-related) who have muscle weakness could be candidates for future trials informed by this work.
Not a fit: People without FSHD, with unrelated causes of muscle weakness, or whose muscles are already irreversibly lost are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could reduce toxic DUX4 in muscles and slow or stop muscle loss in people with FSHD.
How similar studies have performed: Related antisense and AAV-based RNA-silencing approaches have shown promise in cells and some animal models, but CRISPR-Cas13 RNA-editing delivered in vivo for FSHD is novel and largely untested.
Where this research is happening
Columbus, United States
- Research Inst Nationwide Children's Hosp — Columbus, United States (Active)
Researchers
- Principal investigator: Harper, Scott Q — Research Inst Nationwide Children's Hosp
- Study coordinator: Harper, Scott Q
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.